Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02620839 · ClinicalTrials.gov registry record · Phase 1
Phase Ib Study of Alpelisib With Cisplatin in Patients With HPV+ Solid Tumor Malignancies
A Phase 1 study, sponsored by Pamela Munster.
- Terminated
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT02620839 is a Phase 1 study that was terminated before completion, run by Pamela Munster. The registered enrollment target is 28 participants.
The verdict
NCT02620839, a Phase 1 study, was terminated before completion, sponsored by Pamela Munster.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
This phase Ib trial studies the best dose and side effects of alpelisib and cisplatin in treating patients with human papillomavirus (HPV) positive solid tumor malignancies. Alpelisib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving alpelisib and cisplatin may work better in treating patients with solid tumor malignancies.
Interventions
- DRUG Cisplatin
- DRUG Alpelisib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2016-12-01 |
| Est. Completion | 2019-01-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02620839
The ClinicalTrials.gov registry entry for NCT02620839 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pamela Munster, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Cisplatin is the first listed.
NCT02620839 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02620839 about?
NCT02620839 is a clinical study titled "Phase Ib Study of Alpelisib With Cisplatin in Patients With HPV+ Solid Tumor Malignancies". This phase Ib trial studies the best dose and side effects of alpelisib and cisplatin in treating patients with human papillomavirus (HPV) positive solid tumor malignancies. Alpelisib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherap...
What is the current status of trial NCT02620839?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2016-12-01. Estimated completion is 2019-01-28.
What interventions are being tested in trial NCT02620839?
The interventions under investigation include: Cisplatin (DRUG), Alpelisib (DRUG).
Who is sponsoring clinical trial NCT02620839?
This trial is sponsored by Pamela Munster, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.